Ken Griffin Reviva Pharmaceuticals Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$0.92 - $2.82 $268,088 - $821,748	291,400 Added 485.67%	351,400 $607,000
Q3 2024 Nov 14, 2024	SELL	$0.64 - $1.48 $29,504 - $68,228	-46,100 Reduced 43.45%	60,000 $86,000
Q2 2024 Aug 14, 2024	SELL	$1.25 - $3.79 $19,625 - $59,503	-15,700 Reduced 12.89%	106,100 $135,000
Q1 2024 May 15, 2024	BUY	$2.76 - $5.52 $191,819 - $383,639	69,500 Added 132.89%	121,800 $460,000
Q4 2023 Feb 14, 2024	SELL	$3.56 - $6.04 $75,472 - $128,048	-21,200 Reduced 28.84%	52,300 $269,000
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.9 $169,694 - $256,060	43,400 Added 144.19%	73,500 $358,000
Q2 2023 Aug 14, 2023	SELL	$4.42 - $8.55 $165,750 - $320,625	-37,500 Reduced 55.47%	30,100 $176,000
Q1 2023 May 15, 2023	SELL	$3.79 - $4.87 $105,741 - $135,873	-27,900 Reduced 29.21%	67,600 $283,000
Q4 2022 Feb 14, 2023	SELL	$1.68 - $5.99 $84,504 - $301,297	-50,300 Reduced 34.5%	95,500 $405,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $2.66 $18,116 - $344,204	129,400 Added 789.02%	145,800 $232,000

7.83M

628K

338K

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $22.1M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.